Honz Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2019
April 27, 2020 at 12:12 pm
Share
Honz Pharmaceutical Co., Ltd. announced earnings results for the full year ended December 31, 2019. For the full year, the company announced sales was CNY 1,008.431 million compared to CNY 882.744 million a year ago. Operating loss was CNY 19.092 million compared to operating Income of CNY 34.111 million a year ago. Net loss was CNY 26.462 million compared to net income of CNY 13.366 million a year ago. Basic loss per share from continuing operations was CNY 0.0588 compared to basic earnings per share from continuing operations of CNY 0.0297 a year ago.
HONZ PHARMACEUTICAL CO., LTD., formerly HAINAN HONZ PHARMACEUTICAL CO., LTD., is principally engaged in the research, development, production and distribution of drugs for children. The Company provides western medicines and Chinese patent drugs, including antipyretic and analgesic drugs, cold drugs, antibiotics drugs, respiratory system drugs, digestant and arresting convulsion drugs, as well as nutrition drugs, among others. The Company's products include nimesulide granules, cefminox sodium for injection, Zhike Juhong granules, Ganmao Qingre granules, artificial cow-bezoar and chlorphenamine maleate granules, cefaclor granules, carbocisteine granules, Jianerle granules, pediatric four vitaminsand calcium gluconate granules, as well as ribavirin pellets and Norfloxacin capsules for adults.